Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

In order to evaluate the efficacy and tolerability of nebivolol during long term treatment of
outpatients with hypertension, 6 open multicentre studies are being carried out in 5 different …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Hypertensive African Americans often respond poorly to β‐blocker monotherapy, compared
with whites. There is evidence, however, that suggests that this response may be different if …

Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …

The purpose of this study was to establish the antihypertensive efficacy and safety of
nebivolol-a novel, highly selective β 1 blocker with nitric-oxide mediated vasodilatory effects …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …